Biocross, SL is a biotechnology-based company established in 2005 as a spin-off of the Spanish National Research Council (CSIC) with the aim of studying new biomarkers for the diagnosis of neurodegenerative diseases and developing reliable blood-based diagnostic methods applicable in hospital settings.
Biocross is developing a series of blood tests for the diagnosis of Alzheimer?s disease, with a view to providing neurologists with an integrated diagnostic solution that can be applied to any disease stage, including the earliest, asymptomatic phase.
Our novel diagnostic approach is made possible by simultaneous analysis of a combination of distinct biomarker types.
Our tests ares designed to discriminate between different forms of dementia to identify and correctly classify patients with Alzheimer's disease.
We offer cost-effective solutions that can be easily incorporated into hospital routines.
- ApoE4 blood marker assay: The ApoE4 blood marker assay is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis. This is achieved using a turbidimetry-based assay with excellent performance in the context of the hospital/clinical settings (100% sensitivity and 96% specificity).
- AD Dementia test: The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. Input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either AD (Alzheimer´s disease), FTD (frontotemporal dementia) or healty.